Disruption of GSH metabolism in acute myeloid leukemia (AML) impairs ABCC1‐mediated efflux of the BCL2 apoptosis regulator (BCL‐2) inhibitor venetoclax, thereby sensitizing malignant cells to this targeted therapy [20]. Here, BCL2 is linked to acute myeloid leukemia.